Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 13/20 | 0.40 |
| ▸ | CTSS | P25774 | 6/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2569629 | 1.00 | JAK3 (0.50) | JAK3BTKCTSKCTSSCACNA1B | |
| SCHEMBL8382498 | 0.90 | JAK3 (0.51) | JAK3BTKCTSKCTSSCACNA1B | |
| SCHEMBL7291726 | 0.90 | JAK3 (0.51) | JAK3BTKCTSKCTSSCACNA1B | |
| SCHEMBL14923490 | 0.90 | JAK3 (0.51) | JAK3BTKCTSKCTSSCACNA1B | |
| SCHEMBL19661523 | 0.87 | JAK3 (0.49) | JAK3BTKCTSKCTSSCACNA1B | |
| SCHEMBL16170320 | 0.86 | JAK3 (0.48) | JAK3BTKCTSKCTSSCACNA1B | |
| SCHEMBL836446 | 0.85 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL6631742 | 0.85 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL3745068 | 0.85 | JAK3 (0.52) | JAK3BTKCTSKCTSSCA1 | |
| SCHEMBL29168313 | 0.85 | JAK3 (0.39) | JAK3BTKCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985860-B2 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | SCHERING CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | JAK3 1192/4885BTK 1414/4885CTSK 1861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.